Clinical trial NCT01502514: Safety and Efficacy of Adipose Derived Stem Cells for Congestive Heart Failure
Official title: An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Intramyocardial and Intravenous Implantation of Autologous Adipose-Derived Stem Cells in Ischemic Congestive Heart Failure Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Ischemic Congestive Heart Failure
Keywords: CHF
ischemia
Heart Failure
Lead sponsor: Ageless Regenerative Institute
Sponsor class: INDUSTRY
Collaborators: name: Instituto de Medicina Regenerativa
First posted: 2011-12-30
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The intent of this clinical study is to answer the questions:

1. Is the proposed treatment safe
2. Is treatment effective in improving the disease pathology of patients with Heart Disease as assessed by a series of measurements indicating improvement, stability, or degradation of a patient's cardiovascular function and exercise capacity?

Detailed description: This will be an open-label, non-randomized, multi-center patient-sponsored study designed to assess the safety and cardiovascular effects of Adipose-derived Stem Cell (ASC) implantation using a catheter delivery system in patients who have experienced myocardial infarction. A percutaneous transluminal endomyocardial injection catheter will be used for delivery of ASCs. The therapy is composed of cells isolated from a patient's own adipose tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.

Eligibility criteria: Inclusion Criteria:

1. Willing and able to sign informed consent
2. Age \>18 years and \< 80 years
3. New York Heart Association (NYHA) Class II-IV
4. Ischemic cardiomyopathy without an acute coronary syndrome during the prior 6 months
5. Left Ventricular Ejection Fraction (LVEF) less than or equal to 40% measured by echocardiography at both local and investigative sites, AND:

   * Well-demarcated region of LV systolic dysfunction.
   * Left ventricular wall without mural thrombus and of thickness greater than 0.5 cm
   * No significant valvular disease including: Moderate-to-severe mitral regurgitation (3-4+), aorticstenosis (valve area \<1.5 cm2), aortic insufficiency (3-4+)
6. Up to date on all age and gender appropriate cancer screening per American Cancer Society

Exclusion Criteria:

1. Limiting symptoms due to non-CHF causes, such as lung disease, peripheral vascular disease, arthritis or other musculoskeletal disorders
2. Inability to complete a 6-minute walk test for any reason
3. Need for intravenous CHF medications, chronic continuous oxygen therapyor oral steroids,
4. Coronary Artery Bypass Graft (CABG) surgery within 60 days prior to screening
5. Planned revascularization within 4 months following enrollment
6. Aortic aneurysm or dilatation (\>3.8 cm by echocardiography or other imaging modality)
7. Peripheral vascular disease at or below the distal aorta that may interfere with catheter use
8. Hemodynamically significant pericardial disease
9. Prior aortic or mitral valve replacement
10. Biventricular pacing device implant within the last 3 months OR whose device is scheduled to be revised following enrollment in this trial
11. Scheduled to receive or history of cardiac transplant, surgical remodeling procedure, left ventricular assist device
12. Stroke within 180 days of screening
13. Positive pregnancy test in women of child bearing potential or who are unwilling to use an acceptable method of contraception.
14. Drug or alcohol dependence
15. Life expectancy of less than 1 year
16. History of cancer (other than non-melanoma skin cancer or in situ cervical cancer) in the last five years
17. Exposure to angiogenic therapy (including myocardial laser) or another investigational drug within 60 days of screening, or enrollment in any concurrent study that may confound the results of this study
18. Any factors in the opinion of the Investigator which render the patient unsuitable for participation that will interfere with conduct of the study or interpretation of the results.

Primary outcomes:
measure: Improvement in 6 Minute Walk Test
timeFrame: 3 months
measure: Improvement in the Minnesota Living with Heart Failure Quality of Life Questionnaire
timeFrame: 3 months
measure: Improvement in 6 Minute Walk Test
timeFrame: 6 months
measure: Improvement in the Minnesota Living with Heart Failure Quality of Life Questionnaire
timeFrame: 6 months
Secondary outcomes:
measure: Improvement in New York Heart Association classification
timeFrame: 3 months
measure: Improvement in the Left Ventricular Ejection Fraction (LVEF)
timeFrame: 3 months
measure: Improvement inn the Left Ventricular Volume
timeFrame: 3 months
measure: Improvement in New York Heart Association classification
timeFrame: 6 months
measure: Improvement in the Left Ventricular Ejection Fraction (LVEF)
timeFrame: 6 months
measure: Improvement in the Left Ventricular Volume
timeFrame: 6 months
Other outcomes:
Locations:
city: Tijuana
country: Mexico
facility: Instituto de Medicina Regenerativa
state: Baja California
Study officials:
affiliation: Instituto de Medicina Regenerativa
name: Juan J Parcero, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Comella K, Parcero J, Bansal H, Perez J, Lopez J, Agrawal A, Ichim T. Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy. J Transl Med. 2016 Jun 2;14(1):158. doi: 10.1186/s12967-016-0918-5.